Home » Archive

Drug Development

Drug Development, Featured, SDBN Blog »

2011 Poll Results: Drug Development, Networking Top Interests

Posted by Mary Canady February 4th, 2011 .
No Comments

Thanks to everyone who took our 2011 poll, the results are IN! See the slideshare presentation below which summarizes the results. Check out the word cloud based on the essay answers, with largest words representing those used the most frequently by respondents, helping you to understand the results as a whole visually. We had a fairly small sample size (37), and still welcome input, leave your response here or on the LinkedIn post.
2011 poll
View more presentations from Mary Canady.

We use the results to plan the 2011 schedule. Here is a …

More...

Drug Development, Headline, SDBN Blog, SDBN Events »

SDBN February 15th Event Featuring Althea Technologies

Posted by Mary Canady January 28th, 2011 .
No Comments

2011 is a new year for San Diego Biotech and we’re hoping that the good news will outweigh the bad. Let’s start off featuring a great company with a long history of success in the region, Althea Technologies. In a recent poll of members the top interest was in hearing about drug development, so you’ll really enjoy hearing about Althea’s contract development and manufacturing which helps drugs reach consumers. Maya Agarwal, Business Processes Supervisor at Althea, will present a talk about the company’s history titled “A San Diego Success Story.” …

More...

Biotechnology, Channels, Conferences, Drug Development, Featured, SDBN Blog »

Flip This Asset: San Diego’s Advanced BioHealing ‘Fixed Up’ Dermagraft for Profit and Growth #BIO2010

Posted by Mary Canady May 5th, 2010 .
No Comments

Wednesday I attended a regenerative medicine-focused breakfast at the BIO convention and learned about San Diego company Advanced BioHealing (ABH), who took a ‘fallen’ asset, Dermagraft, and not only turned it into an $85M/year product, but is also looking for new indications. Dermagraft was sold by Advanced Tissue Sciences, who had invested hundreds of millions into developing it, and even got FDA approval for the product to treat diabetic foot ulcers.
I spoke with Advanced BioHealing’s Senior VP Dean Tozer, and he describes their methodology as ‘reverse biotech,’ meaning that they …

More...

Biotechnology, Conferences, Drug Development, Featured, SDBN Blog »

How Does Biomarker Stratification Affect Drug Development Cost? It Depends. #BIO2010

Posted by Mary Canady May 5th, 2010 .
No Comments

On the San Diego Biotechnology Network LinkedIn group, we asked you what you wanted to hear about from the BIO Convention in Chicago, and you requested to hear about Biomarkers. Tuesday I attended a breakout session titled ‘Impact of Biomarkers on Drug Development Complexity and Cost,’ and it described a study done by panel members Federico Goodsaid of the FDA, Michael Palmer of Adaptive Pharmacogenomics, Mark Trusheim of MIT, Steven Averbuch of BMS, Theresa Long of the Van Andel Institute. The study modeled different scenarios utilizing biomarker information and the …

More...

Drug Development, SDBN Blog, SDBN Events, SDBN Feed »

San Diego Biotechnology Network Partner Event May 27th: Rondaxe Drug Development Symposium

Posted by Mary Canady April 22nd, 2010 .
No Comments

Drug development is an area that, according to our 2010 poll, you are interested in, and in previous meetings we’ve discussed that San Diego biotech could grow if we would better complement our drug discovery capabilities with drug development. The SDBN was approached by Rondaxe, a drug development services company, with an idea for an event which will highlight companies they work with from outside the San Diego region. The event will be held May 27th, from 9:00 a.m. to 2:15 p.m., and a light breakfast and lunch will be …

More...